dc.identifier.uri |
http://dx.doi.org/10.15488/512 |
|
dc.identifier.uri |
http://www.repo.uni-hannover.de/handle/123456789/536 |
|
dc.contributor.author |
Donner, Jannik
|
|
dc.contributor.author |
Reck, Michael
|
|
dc.contributor.author |
Bergmann, Simone
|
|
dc.contributor.author |
Kirschning, Andreas
|
|
dc.contributor.author |
Müller, Rolf
|
|
dc.contributor.author |
Wagner-Döbler, Irene
|
|
dc.date.accessioned |
2016-09-06T07:58:00Z |
|
dc.date.available |
2016-09-06T07:58:00Z |
|
dc.date.issued |
2016 |
|
dc.identifier.citation |
Donner, Jannik; Reck, Michael; Bergmann, Simone; Kirschning, Andreas; Muller, Rolf; Wagner-Dobler, Irene: The biofilm inhibitor Carolacton inhibits planktonic growth of virulent pneumococci via a conserved target. In: Scientific Reports 6 (2016), 29677. DOI: http://dx.doi.org/10.1038/srep29677 |
|
dc.description.abstract |
New antibacterial compounds, preferentially exploiting novel cellular targets, are urgently needed to fight the increasing resistance of pathogens against conventional antibiotics. Here we demonstrate that Carolacton, a myxobacterial secondary metabolite previously shown to damage Streptococcus mutans biofilms, inhibits planktonic growth of Streptococcus pneumoniae TIGR4 and multidrug-resistant clinical isolates of serotype 19A at nanomolar concentrations. A Carolacton diastereomer is inactive in both streptococci, indicating a highly specific interaction with a conserved cellular target. S. mutans requires the eukaryotic-like serine/threonine protein kinase PknB and the cysteine metabolism regulator CysR for susceptibility to Carolacton, whereas their homologues are not needed in S. pneumoniae, suggesting a specific function for S. mutans biofilms only. A bactericidal effect of Carolacton was observed for S. pneumoniae TIGR4, with a reduction of cell numbers by 3 log units. The clinical pneumonia isolate Sp49 showed immediate growth arrest and cell lysis, suggesting a bacteriolytic effect of Carolacton. Carolacton treatment caused a reduction in membrane potential, but not membrane integrity, and transcriptome analysis revealed compensatory reactions of the cell. Our data show that Carolacton might have potential for treating pneumococcal infections. |
eng |
dc.description.sponsorship |
BMBF/031A299 |
|
dc.description.sponsorship |
HGF/VH-GS-202 |
|
dc.language.iso |
eng |
|
dc.publisher |
London : Macmillan Publishers Limited |
|
dc.relation.ispartofseries |
Scientific Reports 6 (2016) |
|
dc.rights |
CC BY 4.0 Unported |
|
dc.rights.uri |
https://creativecommons.org/licenses/by/4.0/ |
|
dc.subject |
Carolacton |
eng |
dc.subject |
S. pneumoniae TIGR4 |
eng |
dc.subject |
Medical Microbiology |
eng |
dc.subject |
Infection Research |
eng |
dc.subject.ddc |
500 | Naturwissenschaften
|
ger |
dc.title |
The biofilm inhibitor Carolacton inhibits planktonic growth of virulent pneumococci via a conserved target |
eng |
dc.type |
Article |
|
dc.type |
Text |
|
dc.relation.essn |
2045-2322 |
|
dc.relation.issn |
2045-2322 |
|
dc.relation.doi |
http://dx.doi.org/10.1038/srep29677 |
|
dc.bibliographicCitation.volume |
6 |
|
dc.bibliographicCitation.firstPage |
29677 |
|
dc.description.version |
publishedVersion |
|
tib.accessRights |
frei zug�nglich |
|